High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
742.35M
+22.77%
0.482
+17.57%
784.52M
+18.23%
0.532
+18.2%
800.67M
+16.01%
0.499
+27.97%
Estimates Revision
The market is revising Upward the revenue expectations for Ryan Specialty Holdings, Inc. (RYAN) for FY2025, with the revenue forecasts being adjusted by 0.15% over the past three months. During the same period, the stock price has changed by -16.11%.
Revenue Estimates for FY2025
Revise Upward
+0.15%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-1.23%
In Past 3 Month
Stock Price
Go Down
-16.11%
In Past 3 Month
9 Analyst Rating
0Wall Street analysts forecast RYAN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RYAN is 75.86 USD with a low forecast of 63.00 USD and a high forecast of 89.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
1 Hold
1 Sell
Moderate Buy
0Current: 58.490
Low
63.00
Averages
75.86
High
89.00
0Current: 58.490
Low
63.00
Averages
75.86
High
89.00
UBS
Buy
downgrade
$84 -> $80
2025-08-04
Reason
UBS
Price Target
$84 -> $80
2025-08-04
downgrade
Buy
Reason
UBS lowered the firm's price target on Ryan Specialty to $80 from $84 and keeps a Buy rating on the shares. The firm updated its model for Property & Casualty and Brokers. UBS cites lower premiums and margins for the price target update.
Morgan Stanley
Overweight
downgrade
$80 -> $78
2025-07-14
Reason
Morgan Stanley
Price Target
$80 -> $78
2025-07-14
downgrade
Overweight
Reason
Morgan Stanley lowered the firm's price target on Ryan Specialty to $78 from $80 and keeps an Overweight rating on the shares.
Wells Fargo
Equal Weight
downgrade
$65 -> $63
2025-07-10
Reason
Wells Fargo
Price Target
$65 -> $63
2025-07-10
downgrade
Equal Weight
Reason
Wells Fargo lowered the firm's price target on Ryan Specialty to $63 from $65 and keeps an Equal Weight rating on the shares ahead of quarterly results. The firm says the focus should be on pricing, loss trend, and reserves for P&C companies, organic and margin for brokers, and sales/VII/capital for life companies.
Barclays
Alex Scott
Overweight
downgrade
$83 -> $79
2025-07-07
Reason
Barclays
Alex Scott
Price Target
$83 -> $79
2025-07-07
downgrade
Overweight
Reason
Barclays analyst Alex Scott lowered the firm's price target on Ryan Specialty to $79 from $83 and keeps an Overweight rating on the shares. Heading into Q2 earnings, the firm is more cautious on property and casualty carriers, saying underwriting margins face pressure from softening rates and unfavorable mix shift. Barclays is more constructive on reinsurers due to "idiosyncratic tailwinds" and capital return potential in the second half of the year. The analyst names Everest Group (EG) and Hartford Insurance (HIG) as top ideas.
Morgan Stanley
Bob Huang
Overweight
maintain
$78 -> $80
2025-05-19
Reason
Morgan Stanley
Bob Huang
Price Target
$78 -> $80
2025-05-19
maintain
Overweight
Reason
Morgan Stanley analyst Bob Huang raised the firm's price target on Ryan Specialty to $80 from $78 and keeps an Overweight rating on the shares. The firm is updating its price targets on stocks under its coverage in the P&C Insurance sector, the analyst tells investors. Results were somewhat mixed depending on the segments, but the firm sees further growth and margin expansion in personal lines, which should be durable in 2025. Heading into 2025, the firm expects broader P&C trend to remain steady, with personal lines and brokers leading on the earnings growth front.
Goldman Sachs
Neutral -> Buy
upgrade
$74 -> $81
2025-05-13
Reason
Goldman Sachs
Price Target
$74 -> $81
2025-05-13
upgrade
Neutral -> Buy
Reason
Goldman Sachs upgraded Ryan Specialty to Buy from Neutral with a price target of $81, up from $74. The company will offer the greatest organic growth, total revenue growth, and margin expansion opportunity in the insurance brokerage coverage universe over the next several years, with a "reasonable valuation considering better-than-peer fundamentals," the analyst tells investors in a research note. The firm expects investors to be forward-looking to the second half of 2025 and beyond, where it believes Ryan can maintain its organic growth gap versus retail insurance brokers.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Ryan Specialty Holdings Inc (RYAN.N) is 25.58, compared to its 5-year average forward P/E of 30.76. For a more detailed relative valuation and DCF analysis to assess Ryan Specialty Holdings Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Undervalued
5Y Average PE
30.76
Current PE
25.58
Overvalued PE
33.43
Undervalued PE
28.09
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Fair
5Y Average EV/EBITDA
10.80
Current EV/EBITDA
10.71
Overvalued EV/EBITDA
11.73
Undervalued EV/EBITDA
9.86
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
2.48
Current PS
2.31
Overvalued PS
2.75
Undervalued PS
2.21
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 53579.79% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
RYAN News & Events
Events Timeline
(ET)
2025-07-31
16:08:44
Ryan Specialty lowers FY25 organic revenue growth rate view to 9%-11%
2025-07-31
16:07:27
Ryan Specialty reports Q2 adjusted EPS 66c, consensus 65c
2025-07-30 (ET)
2025-07-30
16:47:10
Markel Insurance to sell reinsurance renewal rights to Nationwide
Sign Up For More Events
Sign Up For More Events
News
Preview
8.0
08-08NASDAQ.COMEx-Dividend Reminder: Chemed, Ryan Specialty Holdings and Cohen & Steers Tax-advantaged Preferred Securities
Preview
8.5
07-31NewsfilterMarkel Insurance announces agreement to sell reinsurance renewal rights to Nationwide
Preview
8.0
07-18NASDAQ.COMRYAN September 19th Options Begin Trading
Sign Up For More News
People Also Watch
FAQ
What is Ryan Specialty Holdings Inc (RYAN) stock price today?
What is Ryan Specialty Holdings Inc (RYAN)'s business?
What is the price predicton of RYAN Stock?
What is Ryan Specialty Holdings Inc (RYAN)'s revenue for the last quarter?
What is Ryan Specialty Holdings Inc (RYAN)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Ryan Specialty Holdings Inc (RYAN)'s fundamentals?
How many employees does Ryan Specialty Holdings Inc (RYAN). have?